Dasatinib + Quercetin clears senescent cells that accumulate with age and drive chronic inflammation. The 2015 breakthrough that's changing how we think about aging.
Last updated: March 2026
Senolytics are drugs that selectively clear senescent cells — "zombie cells" that have stopped dividing but refuse to die. Instead, they secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP) that drive age-related diseases.
Senescent cells accumulate with age. They don't function but also don't die — hence "zombie." They secrete IL-6, TNF-α, and other inflammatory factors that accelerate aging.
The most studied senolytic combo. D (cancer drug) + Q (flavonoid). First shown to clear senescent cells in 2015 by Kirkland & Tchkonia at Mayo Clinic.
Senolytics are not taken continuously. Protocol: 3 days on, weeks off. This allows new senescent cells to accumulate before the next cycle.
Senolytic treatment reduces SASP factors by ~50% in mouse studies. This lowers systemic inflammation and improves physical function.
Breakthrough: The 2015 paper (Kirkland & Tchkonia) showed that clearing just 30% of senescent cells extended lifespan by 30% in mice. This launched the senolytic field.
Important: Dasatinib requires prescription. Quercetin is OTC. Start low to assess tolerance. Must have medical supervision for D portion.
• Dasatinib: Prescription cancer drug — requires doctor oversight
• Bone marrow suppression: Possible cytopenias
• Fluid retention: Monitor for edema
• Quercetin: Generally well-tolerated
• Off-label use: Senolytic protocols are experimental
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. Dasatinib is a prescription cancer drug. Never use without medical supervision. Consult a healthcare provider.